- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Benefits of physical activity.
Displaying page 1 of 2.
EudraCT Number: 2013-003619-24 | Sponsor Protocol Number: bolpecocdpde | Start Date*: 2014-02-26 |
Sponsor Name:Lourdes Lozano-Bailen | ||
Full Title: Benefits of liquid oxygen in COPD patients without evidence of domiciliary oxygen therapy, presenting desaturation on exertion. | ||
Medical condition: Moderate to severe COPD patients: FEV1 <70%, FEV1/FVC <70%, TLC> 80% of the reference values (GesEPOC Stadium II-IV/GOLD III-IV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001387-39 | Sponsor Protocol Number: 1.4 | Start Date*: 2019-03-15 |
Sponsor Name:Thoraxklinik-Heidelberg gGmbH | ||
Full Title: A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial h... | ||
Medical condition: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002482-20 | Sponsor Protocol Number: NUMACT 1 | Start Date*: 2005-12-02 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | ||
Full Title: A Pilot Study to Test the Effect of Treating Depression Associated with Rueumatoid Arthritis (RA) using Venlaflaxine | ||
Medical condition: Symptoms of Depression as defined by the Hospital Anxiety and Depression Questionnaire associated with Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-002424-42 | Sponsor Protocol Number: 2006-002 | Start Date*: 2006-03-20 | |||||||||||
Sponsor Name:OSPEDALE SACRO CUORE-DON CALABRIA | |||||||||||||
Full Title: Evaluation of Safety and Efficacy on Visual Acuity Outcome and Choroidal Neovascularization of Intravitreal Somministration of Bevacizumab Avastin, Roche, United Kingdom in patients with Subfovea... | |||||||||||||
Medical condition: Subfoveal Choroidal Neovascularization due to Age Related Macular Degeneration who did not respond to currently available treatments | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005341-11 | Sponsor Protocol Number: rhASA-01 | Start Date*: 2006-12-28 | |||||||||||
Sponsor Name:Shire Pharmaceuticals Ireland Limited | |||||||||||||
Full Title: A single center, open-label, non-randomized, uncontrolled, multiple-dose, dose escalation study of the safety, pharmacokinetics and efficacy of Metazym (recombinant human arylsulfatase A or rhASA) ... | |||||||||||||
Medical condition: Late infantile metachromatic leukodystrophy (MLD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000287-17 | Sponsor Protocol Number: RC12-01 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:FONDAZIONE SANTA LUCIA | |||||||||||||
Full Title: PROMOTION OF FUNCTIONAL RESTORATION THROUGH PHARMACOLOGICAL MODULATION OF BRAIN PLASTICITY WITH AMINOPYRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS STUDIED BY FUNCTIONAL MRI | |||||||||||||
Medical condition: Patients with MS, without relevant medical conditions, with right upper limb impairment assessed by a hand dexterity test will be included.Patients will be in a non-active phase of the disease and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000712-30 | Sponsor Protocol Number: ABR-71432 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation | |||||||||||||
Medical condition: Posttraumatic Stress Disorder (PTSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001236-65 | Sponsor Protocol Number: GS-US-312-0119 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) GB (Completed) SE (Completed) ES (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000764-30 | Sponsor Protocol Number: HOT-LOCO | Start Date*: 2021-07-06 | |||||||||||||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||||||||||||
Full Title: Hyperbaric Oxygen for Treatment of Long COVID syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial | |||||||||||||||||||||||
Medical condition: Long COVID, post-acute COVID-19 Syndrome, post COVID-19 Syndrome (ICD-10 U09.0) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005318-50 | Sponsor Protocol Number: M-40464-33 | Start Date*: 2015-05-04 | |||||||||||
Sponsor Name:AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden | |||||||||||||
Full Title: A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, ... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004013-13 | Sponsor Protocol Number: GS-US-313-0124 | Start Date*: 2013-10-31 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Ly... | |||||||||||||
Medical condition: Indolent Non-Hodgkin Lymphomas •Follicular lymphoma •Small lymphocytic lymphoma •Lymphoplasmacytic lymphoma (with or without Waldenström macroglobulinemia) •Marginal zone lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) SE (Prematurely Ended) ES (Completed) HU (Completed) CZ (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002765-34 | Sponsor Protocol Number: MabionCD20-003RA | Start Date*: 2021-10-21 | |||||||||||
Sponsor Name:Mabion S.A. | |||||||||||||
Full Title: A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20 (manufactured in commercial scale), EU-approved MabThera® and US-licen... | |||||||||||||
Medical condition: Moderate-to-severe rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003390-95 | Sponsor Protocol Number: WN28745 | Start Date*: 2014-02-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease: Part II: Open-label exten... | |||||||||||||
Medical condition: MILD ALZHEIMER’S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) ES (Completed) PT (Completed) IT (Completed) NL (Completed) BE (Completed) HU (Completed) FI (Completed) BG (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001056-17 | Sponsor Protocol Number: 3606 | Start Date*: 2020-08-14 | ||||||||||||||||
Sponsor Name:Kings's College London [...] | ||||||||||||||||||
Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia. | ||||||||||||||||||
Medical condition: Clinically significant agitation in Alzheimer's Diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002700-14 | Sponsor Protocol Number: NA-0113-200-EU | Start Date*: 2018-12-14 | |||||||||||
Sponsor Name:Navad Life Sciences Pte Ltd | |||||||||||||
Full Title: Single-center, open-label, adaptive design study to evaluate the influence on hormonal and ovarian function and vaginal bleeding pattern of different dosages of levonorgestrel administered once dai... | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004359-35 | Sponsor Protocol Number: ICEA2020.1 | Start Date*: 2020-10-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Induction of Cure in Early Arthritis | |||||||||||||
Medical condition: early unclassified arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003768-55 | Sponsor Protocol Number: RDEA594-304 | Start Date*: 2012-05-14 | |||||||||||
Sponsor Name:Ardea Biosciences, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering S... | |||||||||||||
Medical condition: Tophaceous Gout | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003703-22 | Sponsor Protocol Number: P2-IMU-838-UC | Start Date*: 2018-05-03 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe u... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) PL (Completed) PT (Completed) HR (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004034-42 | Sponsor Protocol Number: GS-US-313-0125 | Start Date*: 2013-10-31 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indole... | |||||||||||||
Medical condition: Indolent Non-Hodgkin Lymphomas •Follicular lymphoma •Small lymphocytic lymphoma •Lymphoplasmacytic lymphoma (with or without Waldenström macroglobulinemia) •Marginal zone lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) SE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
